Tackling Chronic Inflammatory Airway Diseases

Target Audience

The educational design of this activity addresses the needs of ear, nose, and throat (ENT) specialists, as well as clinical immunologists/allergists and pulmonologists who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP) or other chronic upper or lower inflammatory diseases (eg, allergic rhinitis, severe asthma).

Program Overview

Chronic inflammatory diseases of the upper and lower airways, including allergic rhinitis, CRSwNP, and asthma, have been tied to significant risks and burdens for affected patients. Although biologic therapies that target overactive cytokine signaling are available, newer therapies are emerging, with targets upstream in the pathogenic cascade to improve efficacy across both T2-high and T2-low profiles. Join us for this engaging Expert Roundtable™ activity to hear multidisciplinary insights related to pathophysiologic processes in chronic inflammatory airway diseases, the rationale and evidence behind new biologic therapies, and integrated therapeutic strategies to achieve global disease control.

Educational Objectives

After completing this activity, the participant should be better able to:

• Discuss pathophysiologic processes that contribute to chronic inflammation, hyper-responsiveness, and remodeling in the upper and lower airways, including the roles of thymic stromal lymphopoietin and implications for treatment
• Describe the clinical profiles and evidence for biologic therapies to address overactive cytokine signaling in patients with chronic inflammatory upper or lower airway diseases, including CRSwNP
• Tailor biologic-based therapeutic regimens for patients with CRSwNP, severe asthma, or allergic rhinitis to address pathophysiologic processes and overcome treatment-related barriers

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Joseph K. Han, MD, FARS, FAAAAI, FAAOA: Consulting Fees: AstraZeneca, GSK, Sanofi

Amber U. Luong, MD, PhD, FACS: Consulting Fees: Aerin Medical, GSK, Lyra Therapeutics, Maxwell Biosciences, Medtronic, Neurent Medical Ltd, Sanofi, Stryker ENT; Contracted Research: Lyra Therapeutics, Sanofi; Ownership Interest (Stock): Aerin Medical; Ownership Interest (Stock Interest): SoundHealth, Inc.

Anju T. Peters, MD, MSCI: Consulting Fees: AstraZeneca, Chiesi, Inc., Eli Lilly, GSK, Merck, Inc., Sanofi Regeneron; Contracted Research: AstraZeneca, Sanofi Regeneron

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 75% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.